Comparative Pharmacology
Head-to-head clinical analysis: AFIRMELLE versus ESTARYLLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AFIRMELLE versus ESTARYLLA.
AFIRMELLE vs ESTARYLLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Estarylla is a combination oral contraceptive containing ethinyl estradiol and norgestimate. It suppresses gonadotropin release (FSH and LH) via estrogen and progestin, inhibiting ovulation. Additionally, it increases cervical mucus viscosity and alters endometrial receptivity, impeding sperm penetration and implantation.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
One tablet (0.02 mg ethinyl estradiol and 0.15 mg desogestrel) orally once daily for 21 days, followed by 7 days of placebo. Hormone-free interval of 7 days.
None Documented
None Documented
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Terminal elimination half-life of ethinyl estradiol is approximately 13-16 hours; clinical context: steady-state achieved within 5-7 days
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Renal: ~55% as metabolites, ~27% unchanged; Fecal: ~45% as metabolites
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive